Видео с ютуба Lenalidomide

Why Is Cancer Drug Revlimid So Expensive?

Lenalidomide's place in the myeloma treatment landscape

Lenalidomid (Revlimid) – lek immunomodulujący (IMiD) w leczeniu szpiczaka mnogiego

The impact of lenalidomide on second primary malignancies: long-term data from the Myeloma XI Trial

What impact do Revlimid® (lenalidomide) and Pomalyst® (pomalidomide) have on the bone marrow?

Lenalidomide for smoldering myeloma

Lenalidomide maintenance – an active approach to treating MM?

Dr. Leonard on Lenalidomide With Rituximab in Follicular Lymphoma

Lenalidomide in hematologic malignancies - Video abstract [ID 81310]

Lenalidomide as a Highly-Effective Maintenance Therapy in Myeloma

Toxicities Associated With Lenalidomide for Multiple Myeloma

Effects of Dose Reductions of Lenalidomide in Myeloma Patients | Jens Hillengass, MD, PhD | ASH 2023

Graham Jackson, MD: Lenalidomide Maintenance Is Effective in All Types of Myeloma Patients

OPTIMISMM: investigating an alternative therapy for lenalidomide-refractory patients

Novel Anti-Cancer Agents for Multiple Myeloma

Lenalidomide maintenance remains best for newly diagnosed MM

Dr. Schuster on Long-Term Outcomes of Lenalidomide and Rituximab in MCL

Benefit of treating smouldering myeloma patients early with lenalidomide & dexamethasone

R2 in the second-line: lenalidomide-rituximab improves PFS in relapsed/refractory NHL

Results of RELEVANCE: frontline rituximab-lenalidomide for follicular lymphoma

Should I interrupt or discontinue therapy in patients with lenalidomide-induced rash?

RE-MIND2: observational study comparing tafasitamab+lenalidomide to available therapies in R/R DLBCL

Dr. LaCasce Discusses the FDA Approval of Lenalidomide/Rituximab in Non-Hodgkin Lymphoma

Evaluating the optimal duration of lenalidomide maintenance after autoSCT using data from Myeloma XI

AFT-41 trial: daratumumab, lenalidomide, ixazomib, and dexamethasone in transplant-ineligible NDMM